⌘K
t
N4 Pharma PLC held its Annual General Meeting on May 23, 2024, where all six proposed resolutions were duly passed. Shareholders approved the annual report and audited accounts for the year ended 31 December 2023 (99.93% 'For'), re-elected Nigel Theobald and David Templeton as Directors (99.32% 'For' each), and re-appointed Saffery Champness LLP as auditor (99.32% 'For'). Directors were also authorised to allot shares (99.10% 'For') and to disapply pre-emption rights (99.00% 'For').
| Date | 23 May 2024 |
| Time | 12:19:39 |
| Category | AGMs and other meetings |
| ID | 6939P |
N4 Pharma plc
("N4 Pharma" or the "Company")
Result of Annual General Meeting
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed.
|
Resolution |
For |
For% |
Against |
Against% |
Total |
Witheld votes* |
|
Ordinary Resolution 1 To receive the annual report and audited accounts for the year ended 31 December 2023 |
20,612,844 |
99.93% |
13,980 |
0.07% |
20,626,824 |
296,841 |
|
Ordinary Resolution 2 To re-elect Nigel Theobald as a Director of the Company |
20,605,744 |
99.32% |
141,080 |
0.68% |
20,746,824 |
176,841 |
|
Ordinary Resolution 3 To re-elect David Templeton as a Director of the Company |
20,605,744 |
99.32% |
141,080 |
0.68% |
20,746,824 |
176,841 |
|
Ordinary Resolution 4 To re-appoint Saffery Champness LLP as the Companyʼs auditor and to authorise the Directors to determine their remuneration |
20,605,644 |
99.32% |
140,980 |
0.68% |
20,746,624 |
177,041 |
|
Ordinary Resolution 5 To authorise the Directors to allot shares |
20,559,085 |
99.10% |
187,539 |
0.90% |
20,746,624 |
177,041 |
|
Special Resolution 6 To disapply pre-emption rights |
20,506,310 |
99.00% |
207,439 |
1.00% |
20,713,749 |
209,916 |
*Please note a vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.
For more information please contact:
|
N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director |
|
|
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Caroline Rowe/Kasia Brzozowska (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) |
Tel: +44(0)20 3470 0470 |
|
InvestorHub Engage with us directly at N4 Pharma Investor Hub |
Sign up at investors.n4pharma.com
https://investors.n4pharma.com/link/Ky0AZe
|
|
Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker James Pope |
Tel: +44(0)20 3657 0050 |
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens in these fields to use Nuvec® as the delivery vehicle for these antigens. As these products progress through pre‐clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.
For further information on the Company visit www.n4pharma.com or sign up at www.investors.n4pharma.com.